Drug profile · INN
vortioxetine hydrobromide
VORTIOXETINE HYDROBROMIDE
vortioxetine hydrobromide (VORTIOXETINE HYDROBROMIDE) is a serotonin transporter inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Drug details — vortioxetine hydrobromide
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.89
Quick answer
vortioxetine hydrobromide (VORTIOXETINE HYDROBROMIDE) is a serotonin transporter inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin transporter inhibitor
Primary target: 5-hydroxytryptamine receptor 1A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is vortioxetine hydrobromide?
vortioxetine hydrobromide (VORTIOXETINE HYDROBROMIDE) is a serotonin transporter inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vortioxetine hydrobromide?
VORTIOXETINE HYDROBROMIDE is a marketed brand name for vortioxetine hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vortioxetine hydrobromide?
vortioxetine hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.